Several other equities analysts have also weighed in on ACHN. Ladenburg Thalmann Financial Services assumed coverage on Achillion Pharmaceuticals in a report on Thursday, February 2nd. They set a buy rating and a $10.00 target price on the stock. Zacks Investment Research lowered Achillion Pharmaceuticals from a hold rating to a sell rating in a report on Wednesday, January 25th. One analyst has rated the stock with a sell rating, three have assigned a hold rating and five have given a buy rating to the company. The company presently has a consensus rating of Hold and an average target price of $10.13.
Achillion Pharmaceuticals (NASDAQ:ACHN) opened at 3.89 on Wednesday. Achillion Pharmaceuticals has a 12-month low of $3.71 and a 12-month high of $10.06. The company’s market cap is $531.84 million. The firm’s 50-day moving average price is $4.12 and its 200-day moving average price is $5.15.
Achillion Pharmaceuticals (NASDAQ:ACHN) last posted its earnings results on Thursday, February 23rd. The biopharmaceutical company reported ($0.03) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.18) by $0.15. The company had revenue of $15 million for the quarter. During the same quarter in the prior year, the business posted $0.12 EPS. Achillion Pharmaceuticals’s quarterly revenue was down 52.5% on a year-over-year basis. Analysts expect that Achillion Pharmaceuticals will post ($0.61) EPS for the current year.
ILLEGAL ACTIVITY WARNING: This report was first reported by Mideast Time and is the sole property of of Mideast Time. If you are reading this report on another website, it was illegally copied and reposted in violation of US & international trademark and copyright laws. The original version of this report can be accessed at https://www.mideasttime.com/achillion-pharmaceuticals-inc-achn-stock-rating-lowered-by-thestreet/1589914.html.
Institutional investors have recently bought and sold shares of the company. Commerzbank Aktiengesellschaft FI raised its position in shares of Achillion Pharmaceuticals by 1.4% in the fourth quarter. Commerzbank Aktiengesellschaft FI now owns 50,102 shares of the biopharmaceutical company’s stock valued at $207,000 after buying an additional 699 shares during the last quarter. Pacad Investment Ltd. raised its position in shares of Achillion Pharmaceuticals by 2.4% in the fourth quarter. Pacad Investment Ltd. now owns 37,800 shares of the biopharmaceutical company’s stock valued at $156,000 after buying an additional 900 shares during the last quarter. Rock Springs Capital Management LP raised its position in shares of Achillion Pharmaceuticals by 0.3% in the third quarter. Rock Springs Capital Management LP now owns 1,316,000 shares of the biopharmaceutical company’s stock valued at $10,660,000 after buying an additional 3,500 shares during the last quarter. Canada Pension Plan Investment Board raised its position in shares of Achillion Pharmaceuticals by 25.4% in the third quarter. Canada Pension Plan Investment Board now owns 35,000 shares of the biopharmaceutical company’s stock valued at $284,000 after buying an additional 7,100 shares during the last quarter. Finally, BlackRock Inc. raised its position in shares of Achillion Pharmaceuticals by 92.4% in the third quarter. BlackRock Inc. now owns 47,440 shares of the biopharmaceutical company’s stock valued at $385,000 after buying an additional 22,788 shares during the last quarter. Institutional investors and hedge funds own 77.85% of the company’s stock.
Achillion Pharmaceuticals Company Profile
Achillion Pharmaceuticals, Inc is a biopharmaceutical company. The Company’s primary business is to discover, develop and commercialize small molecule therapeutics for the treatment of infectious diseases and immune system disorders. The Company is focused on its complement inhibitor platform, directed at advancing small molecule compounds that have the potential to be used in the treatment of immune-related diseases associated with the complement system.
Receive News & Ratings for Achillion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achillion Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.